2004
Increased Brain GABA Concentrations Following Acute Administration of a Selective Serotonin Reuptake Inhibitor
Bhagwagar Z, Wylezinska M, Taylor M, Jezzard P, Matthews P, Cowen P. Increased Brain GABA Concentrations Following Acute Administration of a Selective Serotonin Reuptake Inhibitor. American Journal Of Psychiatry 2004, 161: 368-370. PMID: 14754790, DOI: 10.1176/appi.ajp.161.2.368.Peer-Reviewed Original ResearchConceptsGamma-aminobutyric acidBrain GABA concentrationsAcute administrationGABA concentrationSelective serotonin reuptake inhibitor citalopramSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitor citalopramCortical gamma-aminobutyric acidActions of SSRIsGABA/creatine ratiosReuptake inhibitor citalopramSerotonin reuptake inhibitorsGABA neuronsSSRI treatmentReuptake inhibitorsIntravenous citalopramDepressed patientsCreatine ratioHealthy volunteersCortical levelOccipital cortexCrossover designMean increaseMagnetic resonance spectroscopyMood improvement
2003
Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients.
Sharpley A, Bhagwagar Z, Hafizi S, Whale W, Gijsman H, Cowen P. Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. The Journal Of Clinical Psychiatry 2003, 64: 192-6. PMID: 12633128, DOI: 10.4088/jcp.v64n0212.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAntidepressive AgentsAntipsychotic AgentsCross-Over StudiesDepressive DisorderDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMaleMiddle AgedPersonality InventoryPlacebosPolysomnographyPsychiatric Status Rating ScalesRisperidoneSleep, REMTreatment OutcomeWakefulnessConceptsRapid eye movement (REM) sleepEye movement sleepDepressed patientsHealthy volunteersRisperidone treatmentMovement sleepREM sleepMedication-resistant depressed patientsTreatment-resistant depressed patientsConventional antidepressant medicationAntidepressant-like effectsAntipsychotic agent risperidoneDepression Rating ScaleMajor depressive disorderDSM-IV criteriaPatients meritRisperidone additionRisperidone augmentationAntidepressant medicationRisperidone administrationSingle doseTherapeutic dosesAugmentation agentsDepressive disorderHealthy subjects
2002
Cortisol modulation of 5-HT-mediated growth hormone release in recovered depressed patients
Bhagwagar Z, Hafizi S, Cowen P. Cortisol modulation of 5-HT-mediated growth hormone release in recovered depressed patients. Journal Of Affective Disorders 2002, 72: 249-255. PMID: 12450642, DOI: 10.1016/s0165-0327(01)00467-0.Peer-Reviewed Original ResearchConceptsGrowth hormone releaseDepressed patientsMajor depressionHormone releaseStress-induced cortisol secretionBrain serotonin functionPlasma GH levelsEffects of cortisolEffect of hydrocortisoneCross-over designStressful life eventsGH responseGH levelsSingle doseCortisol secretionGH releaseHealthy controlsSerotonin functionRecurrent depressionTRP infusionHealthy volunteersCortisol modulationDepressive symptomatologyDepressed subjectsEuthymic subjectsAcute citalopram administration produces correlated increases in plasma and salivary cortisol
Bhagwagar Z, Hafizi S, Cowen P. Acute citalopram administration produces correlated increases in plasma and salivary cortisol. Psychopharmacology 2002, 163: 118-120. PMID: 12185409, DOI: 10.1007/s00213-002-1149-4.Peer-Reviewed Original ResearchConceptsSalivary cortisol levelsCortisol levelsSelective serotonin re-uptake inhibitorsSalivary cortisolSerotonin re-uptake inhibitorsAcute citalopram administrationRe-uptake inhibitorsCross-over designSalivary cortisol concentrationsCitalopram administrationIntravenous administrationCortisol releaseHealthy volunteersCortisol concentrationsSaliva cortisolCitalopramCortisolParallel increaseAdministrationCorrelated increaseAcceptable means
1999
Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors?
Whale R, Bhagwagar Z, Cowen P. Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors? Psychopharmacology 1999, 145: 223-226. PMID: 10463324, DOI: 10.1007/s002130051052.Peer-Reviewed Original ResearchConceptsPlasma growth hormoneGrowth hormoneCross-over design studyEffect of ketanserinGrowth hormone responsePathophysiology of depressionGrowth hormone releaseNeuroendocrine probeAntidepressant medicationHealthy menReceptor agonistReceptor subtypesHormone releaseHealthy volunteersBlood samplesNeuroendocrine profilePlasma prolactinAgonist activityHormone responseReceptor functionAssay of prolactinZolmitriptanHormoneOral temperatureMode of action